IL260965B - The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures - Google Patents
The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structuresInfo
- Publication number
- IL260965B IL260965B IL260965A IL26096518A IL260965B IL 260965 B IL260965 B IL 260965B IL 260965 A IL260965 A IL 260965A IL 26096518 A IL26096518 A IL 26096518A IL 260965 B IL260965 B IL 260965B
- Authority
- IL
- Israel
- Prior art keywords
- crystalline forms
- maleate salt
- preparation methods
- tlr7 agonist
- maleate
- Prior art date
Links
- 150000002688 maleic acid derivatives Chemical class 0.000 title 2
- 229940124615 TLR 7 agonist Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610082030.0A CN107043380A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| PCT/CN2017/072890 WO2017133683A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL260965B true IL260965B (en) | 2022-02-01 |
Family
ID=59500111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL260965A IL260965B (en) | 2016-02-05 | 2018-08-02 | The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10780091B2 (https=) |
| EP (1) | EP3412671B1 (https=) |
| JP (1) | JP6898336B2 (https=) |
| KR (1) | KR102393279B1 (https=) |
| CN (2) | CN107043380A (https=) |
| AR (1) | AR107547A1 (https=) |
| AU (1) | AU2017215800B2 (https=) |
| CA (1) | CA3013682C (https=) |
| CL (1) | CL2018002089A1 (https=) |
| DK (1) | DK3412671T3 (https=) |
| EA (1) | EA038794B1 (https=) |
| ES (1) | ES2834303T3 (https=) |
| HU (1) | HUE052211T2 (https=) |
| IL (1) | IL260965B (https=) |
| MX (1) | MX374295B (https=) |
| MY (1) | MY196762A (https=) |
| NZ (1) | NZ745231A (https=) |
| PH (1) | PH12018501644B1 (https=) |
| SG (1) | SG11201806682TA (https=) |
| TW (1) | TWI778951B (https=) |
| UA (1) | UA123781C2 (https=) |
| WO (1) | WO2017133683A1 (https=) |
| ZA (1) | ZA201805185B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN112105620B (zh) * | 2018-05-25 | 2026-02-24 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| JP7811014B2 (ja) | 2020-03-02 | 2026-02-04 | プロジェニア インコーポレイテッド | 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法 |
| CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| ATE283855T1 (de) | 1996-07-03 | 2004-12-15 | Sumitomo Pharma | Neue purinderivate |
| NZ504800A (en) | 1997-11-28 | 2001-10-26 | Sumitomo Pharma | 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof |
| ES2577514T3 (es) | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
| CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| CA2707030A1 (en) | 2007-08-03 | 2009-02-12 | Pfizer Limited | Imidazopyridinones |
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| EP2670244B1 (en) | 2011-02-04 | 2018-04-11 | Duquesne University of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2800569B1 (en) | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| LT2906563T (lt) * | 2012-10-10 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui |
| US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| KR20150085081A (ko) | 2012-11-20 | 2015-07-22 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
| MX358025B (es) | 2012-11-20 | 2018-08-02 | Glaxosmithkline Llc Star | Compuestos novedosos. |
| KR20160124157A (ko) | 2014-02-20 | 2016-10-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체 |
| JP6484253B2 (ja) * | 2014-05-01 | 2019-03-13 | ノバルティス アーゲー | Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物 |
| EA032487B1 (ru) | 2014-05-01 | 2019-06-28 | Новартис Аг | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 |
| HUE054672T2 (hu) | 2014-08-15 | 2021-09-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| TWI714661B (zh) | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
| CA3004173C (en) | 2015-11-05 | 2020-07-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 7-(thiazol-5-yl)pyrrolopyrimidine compound as tlr7 agonist |
| CR20180310A (es) | 2015-11-05 | 2018-11-30 | Basf Se | Oxadiazoles sustituidos para combatir hongod fitopatógenos |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043377A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
-
2016
- 2016-02-05 CN CN201610082030.0A patent/CN107043380A/zh active Pending
-
2017
- 2017-02-03 TW TW106103694A patent/TWI778951B/zh active
- 2017-02-04 MX MX2018009500A patent/MX374295B/es active IP Right Grant
- 2017-02-04 JP JP2018540750A patent/JP6898336B2/ja active Active
- 2017-02-04 NZ NZ745231A patent/NZ745231A/en unknown
- 2017-02-04 ES ES17747003T patent/ES2834303T3/es active Active
- 2017-02-04 KR KR1020187024626A patent/KR102393279B1/ko active Active
- 2017-02-04 DK DK17747003.6T patent/DK3412671T3/da active
- 2017-02-04 WO PCT/CN2017/072890 patent/WO2017133683A1/zh not_active Ceased
- 2017-02-04 AU AU2017215800A patent/AU2017215800B2/en active Active
- 2017-02-04 PH PH1/2018/501644A patent/PH12018501644B1/en unknown
- 2017-02-04 EP EP17747003.6A patent/EP3412671B1/en active Active
- 2017-02-04 HU HUE17747003A patent/HUE052211T2/hu unknown
- 2017-02-04 SG SG11201806682TA patent/SG11201806682TA/en unknown
- 2017-02-04 MY MYPI2018702706A patent/MY196762A/en unknown
- 2017-02-04 CA CA3013682A patent/CA3013682C/en active Active
- 2017-02-04 CN CN201780009746.0A patent/CN108602830B/zh active Active
- 2017-02-04 US US16/075,080 patent/US10780091B2/en active Active
- 2017-02-04 EA EA201891770A patent/EA038794B1/ru unknown
- 2017-02-04 UA UAA201809085A patent/UA123781C2/uk unknown
- 2017-02-06 AR ARP170100296A patent/AR107547A1/es active IP Right Grant
-
2018
- 2018-08-01 ZA ZA2018/05185A patent/ZA201805185B/en unknown
- 2018-08-02 IL IL260965A patent/IL260965B/en unknown
- 2018-08-03 CL CL2018002089A patent/CL2018002089A1/es unknown
-
2020
- 2020-08-12 US US16/991,639 patent/US20200368241A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260965B (en) | The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures | |
| IL260981B (en) | The trifluoroacetate salt of the tlr7 agonist type b crystal structure, preparation, and methods of use | |
| CA3290585A1 (en) | Berberine-ursodeoxycholic salt, method of preparation and application therof | |
| IL265730A (en) | Crystalline forms and salts of ppar agonist compounds | |
| IL260968B (en) | Type a crystal structure of trl7 agonist, methods of preparation and its uses | |
| HUE072197T2 (hu) | Ozanimod és ozanimod-hidroklorid kristályos alakjai és eljárások azok elõállítására | |
| IL253360A0 (en) | New crystalline forms of neratinib malate and a process for their preparation | |
| PT3580219T (pt) | Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam | |
| PL3428159T3 (pl) | Postacie krystaliczne soli mesylanowej pochodnej pirydynyloaminopirymidyny, sposoby ich wytwarzania i ich zastosowania | |
| IL253204A0 (en) | Trifluoroacethydrazide compound, method for its preparation and use for preparing a medical preparation | |
| ZA201704743B (en) | Mangiferin-6-o-berberine salt and preparation method and use thereof | |
| IL272108A (en) | New crystal structures of vilanterol tripentate and processes for their preparation | |
| EP3677575A4 (en) | CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR | |
| EP3530650A4 (en) | CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF | |
| EP3327012A4 (en) | Crystalline forms of bilastine and preparation methods thereof | |
| EP3302099A4 (en) | Enhanced salt compositions and methods of preparation thereof | |
| EP3277098A4 (en) | Novel and useful edible salt and methods of use and production thereof | |
| EP3216791A4 (en) | Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof | |
| ME03727B (me) | Zamjena za so i njena primena | |
| IL246835A0 (en) | Improved process for the preparation of trazodone and its hydrochloride salt | |
| PT3398946T (pt) | Sal de derivado de morfolina e a sua forma cristalina, bem como método de preparação, composição farmacêutica e a sua utilização | |
| IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
| GB201809809D0 (en) | Novel crystalline form of tribenuron-methyl, process for preparation and use thereof | |
| SG11201708692WA (en) | Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof | |
| EP3110459A4 (en) | Biocidal composition, preparation and methods of use thereof |